Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Google Secures Pentagon AI Deal for Classified Projects 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
NEW YORK, April 28, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased INSYS Therapeutics, Inc. (“INSYS”) (NASDAQ:INSY) securities between February 23, 2016 and March 15, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/insys-therapeutics-inc-3. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) accordingly, the Company lacked effective internal controls over financial reporting; and (4) as a result, INSYS public statements were materially false and misleading at all relevant times.
If you suffered a loss in INSYS you have until May 16, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/insys-therapeutics-inc-3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
